We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New High Precision Kits Available for Gyros Immunoassay Platform

By LabMedica International staff writers
Posted on 31 Mar 2014
New ready-to-use kits designed for the Gyros high-throughput immunoassay platform will enable generation of high quality data for clinical research and drug development faster than typical ELISA kits.

EMD Millipore, life sciences division of Merck KGaA (Darmstadt, Germany) has released its initial set of "GyroMark HT" immunoassay kits, 5 new kits designed specifically for use on the "Gyrolab xP" workstation from Gyros AB (Uppsala, Sweden). More...
Traditional ELISAs can consume significant time, sample, and reagents. With the automated, walk-away system from Gyros, up to 480 data points can be generated in a single run using less sample and reagents. The initial launch includes assays for important metabolic and toxicity biomarkers, such as GLP-1, insulin, clusterin, and KIM-1. EMD Millipore plans to release additional kits this year and offers custom kits for companies with specific needs or unique or novel antibodies.

The GyroMark HT kits are fully qualified for reliable use in clinical research and feature simple, automated, nanoliter-scale assays requiring as little as 1 µL of sample – with assay precision and accuracy that meet or exceed ELISA performance. “We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” said Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.

Employing microfluidic technology with parallel processing, the Gyros platform offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays further provide: accuracy over a four-log dynamic range (compared to two logs for ELISAs); elimination of cross-talk and plate position artifacts; and simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference.

Maria Hjortsmark, Gyros’ Global Marketing Director, commented, “Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale, and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits to further reduce time-to-results, freeing up analyst time and offering an easier route to robust, reproducible data.”

Related Links:

Gyros
EMD Millipore



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.